Company Overview of Valens Pharma Ltd.
Valens Pharma Ltd., a biopharmaceutical company, focuses on commercializing drug product candidates in the class of energy metabolism agents, referred to as PDK blockers. Its technology is focused on metabolic modulation, through the use of dichloroacetate (DCA) and related compounds. The company’s DCA i.v. product in the PDK Blocker platform includes earlier stage compounds that target the treatment of cardiovascular disease, as well as related metabolic conditions, such as diabetes. Valens Pharma Ltd. was formerly known as CardioMetabolics, Inc. The company was founded in 2000 and is based in Edmonton, Canada.
8308 114 Street NW
Edmonton, AB T6G 2E1
Founded in 2000
Key Executives for Valens Pharma Ltd.
Similar Private Companies By Industry
|9037136 Canada Inc.||Americas|
|AAA Heidelberg Inc.||Americas|
|Ab Biotech Inc.||Americas|
|AB Laboratories Inc.||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Valens Pharma Ltd., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.